SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-043009
Filing Date
2023-11-29
Accepted
2023-11-29 09:24:43
Documents
14
Period of Report
2023-11-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 57556
2 ex4-6b.htm EX-4.6B 21929
3 ex99-1.htm EX-99.1 16563
  Complete submission text file 0001493152-23-043009.txt   283440

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ensc-20231129.xsd EX-101.SCH 3012
5 XBRL LABEL FILE ensc-20231129_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ensc-20231129_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3431
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 231448804
SIC: 2834 Pharmaceutical Preparations